|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group, : Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al West Japan Oncology Group, : Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica, : Erlotinib versus
standard chemotherapy as first-line treatment for European patients
with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kawaguchi T, Matsumura A, Fukai S, Tamura
A, Saito R, Zell JA, Maruyama Y, Ziogas A, Kawahara M and Ou SH
Ignatius: Japanese ethnicity compared with Caucasian ethnicity and
never-smoking status are independent favorable prognostic factors
for overall survival in non-small cell lung cancer: A collaborative
epidemiologic study of the National Hospital Organization Study
Group for Lung Cancer (NHSGLC) in Japan and a Southern California
Regional Cancer Registry databases. J Thorac Oncol. 5:1001–1010.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al Spanish Lung Cancer Group, : Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med.
361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saijo N, Takeuchi M and Kunitoh H: Reasons
for response differences seen in the V15-32, INTEREST and IPASS
trials. Nat Rev Clin Oncol. 6:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM,
Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, et al: Afatinib for
patients with lung adenocarcinoma and epidermal growth factor
receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol.
13:539–548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:pp. 20932–20937. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zakowski MF, Ladanyi M and Kris MG;
Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome
Group, : EGFR mutations in small-cell lung cancers in patients who
have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chmielecki J, Foo J, Oxnard GR, Hutchinson
K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, et al:
Optimization of dosing for EGFR-mutant non-small cell lung cancer
with evolutionary cancer modeling. Sci Transl Med. 3:90ra592011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaft JE, Oxnard GR, Sima CS, Kris MG,
Miller VA and Riely GJ: Disease flare after tyrosine kinase
inhibitor discontinuation in patients with EGFR-mutant lung cancer
and acquired resistance to erlotinib or gefitinib: Implications for
clinical trial design. Clin Cancer Res. 17:6298–6303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergman B, Brezicka FT, Engström CP and
Larsson S: Clinical usefulness of serum assays of neuron-specific
enolase, carcinoembryonic antigen and CA-50 antigen in the
diagnosis of lung cancer. Eur J Cancer. 29A:198–202. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kleisbauer JP, Castelnau O, Thomas P,
Ramirez J, Lanteaume A and Roux F: Prognostic value of
pre-therapeutic levels of carcino-embryonic antigen in primary
bronchial carcinoma]. Bull Cancer. 82:1019–1024. 1995.(In French).
PubMed/NCBI
|
|
21
|
Kulpa J, Wójcik E, Reinfuss M and
Kołodziejski L: Carcinoembryonic antigen, squamous cell carcinoma
antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell
lung cancer patients. Clin Chem. 48:1931–1937. 2002.PubMed/NCBI
|
|
22
|
Nisman B, Lafair J, Heching N, Lyass O,
Baras M, Peretz T and Barak V: Evaluation of tissue polypeptide
specific antigen, CYFRA 21-1, and carcinoembryonic antigen in
nonsmall cell lung carcinoma: Does the combined use of cytokeratin
markers give any additional information? Cancer. 82:1850–1859.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung M, Kim SH, Hong S, Kang YA, Kim SK,
Chang J, Rha SY, Kim JH, Kim DJ and Cho BC: Prognostic and
predictive value of carcinoembryonic antigen and cytokeratin-19
fragments levels in advanced non-small cell lung cancer patients
treated with gefitinib or erlotinib. Yonsei Med J. 53:931–939.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okamoto T, Nakamura T, Ikeda J, Maruyama
R, Shoji F, Miyake T, Wataya H and Ichinose Y: Serum
carcinoembryonic antigen as a predictive marker for sensitivity to
gefitinib in advanced non-small cell lung cancer. Eur J Cancer.
41:1286–1290. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marshall HM, Leong SC, Bowman RV, Yang IA
and Fong KM: The science behind the 7th edition Tumour, Node,
Metastasis staging system for lung cancer. Respirology. 17:247–260.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brundage MD, Davies D and Mackillop WJ:
Prognostic factors in non-small cell lung cancer: A decade of
progress. Chest. 122:1037–1057. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Desch CE, Benson AB III, Somerfield MR,
Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS
and Petrelli NJ; American Society of Clinical Oncology, :
Colorectal cancer surveillance: 2005 update of an American Society
of Clinical Oncology practice guideline. J Clin Oncol.
23:8512–8519. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin JK, Lin CC, Yang SH, Wang HS, Jiang
JK, Lan YT, Lin TC, Li AF, Chen WS and Chang SC: Early
postoperative CEA level is a better prognostic indicator than is
preoperative CEA level in predicting prognosis of patients with
curable colorectal cancer. Int J Colorectal Dis. 26:1135–1141.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee WS, Baek JH, Kim KK and Park YH: The
prognostic significant of percentage drop in serum CEA post
curative resection for colon cancer. Surg Oncol. 21:45–51. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kozu Y, Maniwa T, Takahashi S, Isaka M,
Ohde Y and Nakajima T: Prognostic significance of postoperative
serum carcinoembryonic antigen levels in patients with completely
resected pathological-stage I non-small cell lung cancer. J
Cardiothorac Surg. 8:1062013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okada M, Nishio W, Sakamoto T, Uchino K,
Yuki T, Nakagawa A and Tsubota N: Prognostic significance of
perioperative serum carcinoembryonic antigen in non-small cell lung
cancer: Analysis of 1,000 consecutive resections for clinical stage
I disease. Ann Thorac Surg. 78:216–221. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foa P, Fornier M, Miceli R, Seregni E,
Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S and
Bombardieri E: Tumour markers CEA NSE, SCC, TPA and CYFRA 21.1 in
resectable non-small cell lung cancer. Anticancer Res. 19(4C):
3613–3618. 1999.PubMed/NCBI
|
|
33
|
Reinmuth N, Brandt B, Semik M, Kunze WP,
Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN and Thomas
M: Prognostic impact of Cyfra21-1 and other serum markers in
completely resected non-small cell lung cancer. Lung Cancer.
36:265–270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L,
Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al: Epidermal growth
factor receptor mutations and their correlation with gefitinib
therapy in patients with non-small cell lung cancer: A
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shoji F, Yoshino I, Yano T, Kometani T,
Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H and Maehara Y:
Serum carcinoembryonic antigen level is associated with epidermal
growth factor receptor mutations in recurrent lung adenocarcinomas.
Cancer. 110:2793–2798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wirth T, Soeth E, Czubayko F and Juhl H:
Inhibition of endogenous carcinoembryonic antigen (CEA) increases
the apoptotic rate of colon cancer cells and inhibits metastatic
tumor growth. Clin Exp Metastasis. 19:155–160. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ordoñez C, Screaton RA, Ilantzis C and
Stanners CP: Human carcinoembryonic antigen functions as a general
inhibitor of anoikis. Cancer Res. 60:3419–3424. 2000.PubMed/NCBI
|
|
39
|
Cappuzzo F, Magrini E, Ceresoli GL,
Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri
A, Damiani S, et al: Akt phosphorylation and gefitinib efficacy in
patients with advanced non-small-cell lung cancer. J Natl Cancer
Inst. 96:1133–1141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang J, Greulich H, Jänne PA, Sellers WR,
Meyerson M and Griffin JD: Epidermal growth factor-independent
transformation of Ba/F3 cells with cancer-derived epidermal growth
factor receptor mutants induces gefitinib-sensitive cell cycle
progression. Cancer Res. 65:8968–8974. 2005. View Article : Google Scholar : PubMed/NCBI
|
